Загрузка...
Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
AIMS: Lenvatinib was recently approved for the treatment of radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Here, we characterized the pharmacokinetic (PK) profile of lenvatinib and identified intrinsic and extrinsic factors that explain interindividual PK variability in humans. METHO...
Сохранить в:
| Опубликовано в: : | Br J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876185/ https://ncbi.nlm.nih.gov/pubmed/26879594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12907 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|